Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 627

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 627
---
termination
(subject to Mr. Aminov executing and delivering a customary general release in favor of the company). “Cause” is defined
in the agreement to include dishonesty, misappropriation, willful misconduct, breach of the agreement, and other customary matters. “Good
Reason” is defined to include a material adverse change in Mr. Aminov’s compensation or duties and level of responsibility.
The employment agreement also contains customary confidentiality and invention-assignment covenants to which Mr. Aminov is subject.

Michelle
Yanez, MBA

On
June 18, 2024, we entered into an employment agreement with Ms. Yanez, pursuant to which Ms. Yanez will serve as our Chief Financial
Officer. Under her employment agreement, Ms. Yanez has agreed to devote reasonable business time and effort to the business and affairs
of the Company. Ms. Yanez’ employment agreement provides that here employment can be terminated by either Ms. Yanez or our company
at any time and for any reason, upon no less than thirty (30) days’ notice. Under the agreement, Ms. Yanez will receive a base
salary of $0.137 million per year. In the event that her employment is terminated by our company
without “Cause” or is terminated by Ms. Yanez for “Good Reason”, Ms. Yanez will be entitled to severance compensation
in the form of salary continuation for a period of three months (subject to Ms. Yanez executing and delivering a customary general release
in favor of the company). “Cause” is defined in the agreement to include dishonesty, misappropriation, willful misconduct,
breach of the agreement, and other customary matters. “Good Reason” is defined to include a material adverse change in Ms.
Yanez’s compensation or duties and level of responsibility. The employment agreement also contains customary confidentiality and
invention-assignment covenants to which Ms. Yanez is subject. The employment agreement also contains customary confidentiality
and invention-assignment covenants to which Ms. Yanez is subject.

Christopher
Chapman, MD

On
August 8, 2024, the Company was made aware of the passing of its Chairman and Chief Executive Officer, Dr. Christopher Chapman. There were no clauses in his employment agreement that had an effect on the Company.

Nathen
Fuentes, CPA

On
June 18,